论文部分内容阅读
肺动脉高压(PAH)是一类以小肺动脉血管重构为特征的恶性肺血管疾病,往往由于肺血管阻力进行性升高而最终导致患者右心衰竭甚至死亡。内源性前列环素缺乏在PAH形成中占有相当重要的作用。前列环素及其类似物是有效的血管扩张剂,并具有抗血小板形成、抗增殖和抗炎作用。本文从4种前列环素类似物的药动学、临床研究、临床应用及整体联合治疗4个方面,阐述前列环素及其类似物在临床治疗PAH中的应用。
Pulmonary hypertension (PAH) is a type of malignant pulmonary vascular disease characterized by remodeling of small pulmonary arteries that often leads to right heart failure and even death in patients with progressive increases in pulmonary vascular resistance. Endogenous prostacyclin deficiency plays a very important role in PAH formation. Prostacyclin and its analogs are potent vasodilators and have anti-platelet-forming, antiproliferative and anti-inflammatory effects. This article describes the application of prostacyclin and its analogues in the clinical treatment of PAH from 4 aspects of pharmacokinetics, clinical research, clinical application and overall combination therapy of 4 kinds of prostacyclin analogues.